Novo Nordisk to Sell Wegovy at Discount for Cash-Paying US Customers
March 5 (Reuters) - Novo Nordisk said on Wednesday it would offer doses of its weight-loss drug Wegovy at a reduced cost of $499 per month for cash-paying customers in the United States, as it looks to stave off growing competition from compounded versions.
Wegovy has a list price of around $1,350 a month, regardless of dosage, not taking any coupons and rebates into account.
US-listed shares of Novo Nordisk jumped 4.9% in premarket trading.
The move comes just a week after rival Eli Lilly cut the price for vials of its own weight-loss drug Zepbound by $50 or more and expanded the range of doses sold through its LillyDirect website.
The Wegovy doses, offered through a program called NovoCare Pharmacy, will be available for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines, the company said.
The development comes after the U.S. Food and Drug Administration said on February 21 that there was no longer a shortage of Novo Nordisk's weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10